论文部分内容阅读
目的:分析研究利妥昔单抗治疗大B细胞淋巴瘤的临床疗效。方法:选取2012年1月至2014年1月符合入选条件的大B细胞淋巴瘤患者52例,随机分为观察组和对照组,每组26例,对照组给予CHOP化疗方案,观察组给予利妥昔单抗联合CHOP化疗方案,观察2组总有效率及不良反应。结果:观察组总有效率为80.77%;对照组总有效率为65.38%,观察组疗效明显高于对照组(P<0.05);观察组患者的不良反应与对照组比较差异不显著(P>0.05)。结论:利妥昔单抗治疗大B细胞淋巴瘤临床缓解率较高,近期疗效好,且不良反应无明显增加。
Objective: To analyze the clinical efficacy of rituximab in the treatment of large B cell lymphoma. Methods: From January 2012 to January 2014, 52 patients with large B-cell lymphoma who met the selection criteria were randomly divided into observation group and control group, with 26 cases in each group. The control group was given CHOP chemotherapy and the observation group was given Toximab combined with CHOP chemotherapy, total effective rate and adverse reactions were observed in two groups. Results: The total effective rate in the observation group was 80.77%; the total effective rate in the control group was 65.38%, and the observation group was significantly higher than the control group (P <0.05); adverse reactions in the observation group were not significantly different from the control group (P> 0.05). Conclusion: Rituximab treatment of large B-cell lymphoma clinical response rate is high, the recent good effect, and no significant increase in adverse reactions.